Results 41 to 50 of about 60,286 (337)

Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Despite the obvious benefits of adding immune checkpoint inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC), real-world data remain scarce.
Soo Han Kim, Eun Jung Jo, Jeongha Mok, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Min Ki Lee, Jung Seop Eom, Mi-Hyun Kim   +8 more
doaj   +1 more source

Atezolizumab for Advanced Alveolar Soft Part Sarcoma.

New England Journal of Medicine, 2023
BACKGROUND Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor prognosis and no established therapy. Recently, encouraging responses to immune checkpoint inhibitors have been reported.
Alice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, N. Moore, Jared C. Foster, James S Hu, B. V. Van Tine, A. Conley, William L Read, Richard F. Riedel, M. Burgess, J. Glod, Elizabeth Davis, P. Merriam, A. Naqash, Kristin K. Fino, Brandon Miller, D. Wilsker, Asma Begum, Katherine V Ferry-Galow, Hari A Deshpande, Gary K. Schwartz, Brian H. Ladle, Scott H. Okuno, Jill C Beck, James L Chen, N. Takebe, Laura K Fogli, Christina L Rosenberger, R. Parchment, J. Doroshow   +30 more
semanticscholar   +1 more source

Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer

New England Journal of Medicine, 2018
Background Unresectable locally advanced or metastatic triple‐negative (hormone‐receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor outcomes.
P. Schmid, S. Adams, H. Rugo, A. Schneeweiss, C. Barrios, H. Iwata, V. Diéras, R. Hegg, S. Im, G. Shaw Wright, V. Henschel, L. Molinero, S. Chui, R. Funke, A. Husain, E. Winer, S. Loi, L. Emens   +17 more
semanticscholar   +1 more source

Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC

JTO Clinical and Research Reports
Introduction: Subcutaneous (SC) atezolizumab, a co-formulation containing atezolizumab and recombinant human hyaluronidase PH20), has been approved for use in more than 50 countries for the same indications as intravenous (IV) atezolizumab.
Federico Cappuzzo, MD, Zanete Zvirbule, MD, Ernesto Korbenfeld, MD, Jaroslaw Kolb-Sielecki, MD, Dolores Isla, MD, PhD, Aleksandra Szczesna, MD, PhD, Amparo Yovanna Castro Sanchez, PhD, Alberto Bustillos, MD, Xiaoyan Liu, PhD, Fiona Young, MbChB, Nadia Tosti, PhD, Marta Freitas Monteiro, MSc, PhD, Margarita Majem, MD, PhD   +12 more
doaj   +1 more source

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC

JTO Clinical and Research Reports, 2020
Introduction: During treatment with immune checkpoint inhibitors, immune-related adverse events sometimes occur, and their management is a critical concern associated with such treatment.
Ryo Toyozawa, MD, Naoki Haratake, MD, PhD, Gouji Toyokawa, MD, PhD, Taichi Matsubara, MD, PhD, Shinkichi Takamori, MD, PhD, Naoko Miura, MD, PhD, Masafumi Yamaguchi, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Takashi Seto, MD, PhD   +8 more
doaj   +1 more source

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination

Frontiers in Drug Safety and Regulation, 2023
Introduction: The combination of atezolizumab, an immune checkpoint inhibitor (ICI), and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is the first choice for systemic therapy in hepatocellular carcinoma.
Takahiro Niimura, Takahiro Niimura, Mitsuhiro Goda, Mitsuhiro Goda, Koji Miyata, Jun Matsumoto, Toshihiko Yoshioka, Toshihiko Yoshioka, Hirofumi Hamano, Hirofumi Hamano, Fuka Aizawa, Fuka Aizawa, Kenta Yagi, Kenta Yagi, Yuki Izawa-Ishizawa, Yuki Izawa-Ishizawa, Yoshito Zamami, Yoshito Zamami, Keisuke Ishizawa, Keisuke Ishizawa, Keisuke Ishizawa   +20 more
doaj   +1 more source

SEOM clinical guidelines for the treatment of non‑small cell lung cancer (2018) [PDF]

, 2018
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular
Carcereny, Enric, García, Y., García-Campelo, Rosario, Guirado, M., Insa, A., Juan, O., Majem, Margarita, Provencio, M., Reguart, Noemi, Trigo, J. M., Universitat Autònoma de Barcelona   +10 more
core   +4 more sources

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects

Frontiers in Oncology, 2018
Purpose: Atezolizumab is a programmed death ligand 1 (PDL-1) blocking antibody that was approved for metastatic non-small cell lung cancer (NSCLC) in patients with disease progression.
Rachel Ryu, Kristina E. Ward
doaj   +1 more source

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT. [PDF]

Liver Int
ABSTRACT Background and Aims The phase II REPLACEMENT study showed promising clinical benefit from atezolizumab plus bevacizumab in transcatheter arterial chemoembolization (TACE)–naïve patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond up‐to‐7 criteria, meeting its primary endpoint of progression‐free survival (PFS).
Ueshima K, Tsuchiya K, Yamashita T, Shimose S, Numata K, Kodama Y, Itoh S, Tanaka Y, Kuroda H, Ohkawa K, Kuzuya T, Ikeda M, Kooka Y, Aikata H, Hiraoka A, Moriguchi M, Tateishi R, Ogasawara S, Yamamoto K, Kudo M.   +19 more
europepmc   +2 more sources

IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Exploratory Analysis of the Phase III Study

Liver Cancer, 2022
Introduction: The Phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC).
Masatoshi Kudo, Richard S. Finn, Peter R. Galle, Andrew X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni   +10 more
doaj   +1 more source